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1. Introduction 
1.1. Pathomechanism of Alzheimer's disease 
Alzheimer's disease (AD), the most common form of dementia in the western -
world, currently affects 18 million people worldwide and has been predicted to almost 
triple by 2050 (Citron, 2004; Hebert et al., 2003). The prevalence of AD increases 
exponentially with age, with up to 15% of the population older than 65 years and 40% of 
those over 85 years affected (Zhu et al., 2004). It will be one of the major public health 
problems during the 21st century because of the increasing age of the elderly population. 
As populations age, diseases related to aging affect more people and are a source of 
growing concern. 
AD is named after Alois Alzheimer, who in 1907 published an account of rapidly 
deteriorating mental illness in a 51-year old woman, August D. This disorder, which was 
later called as an eponyme Alzheimer's Disease, was for a long time not recognized as 
different from a common dementia. Studies since the 1980's however, have, revealed 
specific genetic and molecular mechanisms underlying the AD pathogenesis (Selkoe, 
2002). AD is characterized by cognitive and emotional impairments associated with a 
progressive loss of memory, a decrease in linguistic abilities, visuospatial process 
impairment and personality changes. The history of the disease usually involves a 
progressive decline, although there may be short plateaus. 
The complexity of the disease arises from the different risk factors (both genetic 
and environmental) that are involved in the development. The early-onset familial AD 
subtype, which accounts for less than 1-5% of all AD cases, is related to genetic 
mutations. Mutations have been identified on three genes: the amyloid precursor protein 
(APP) gene on chromosome 21, the presenilin 1 gene on chromosome 14 and the 
presenilin 2 gene on chromosome 1 (Suh and Checler, 2002). There are other genes that 
are considered susceptibility or risk factors for sporadic (late-onset) AD. These include 
apolipoprotein E (apoE) (Poirier, 1996), the K- variant of butyrylcholinesterase (BChE) 
(Lehmann et al., 1997) and several mitochondrial genes (Law et al., 2001). 
Epidemiological studies have demonstrated the importance of risk factors for AD 
that include age, female gender, previous head injury and cardiovascular disease (CVD) 
(Law etal., 2001). 
9 
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Fig. 1. The sequence of pathogenic events leading to AD (modified after Hardy andSelkoe, 2002) 
1.2. The amyloid hypothesis 
AD is neuropathologically characterized by progressive degeneration of the 
neuronal cells, particularly cholinergic, especially in the parietal, temporal and frontal 
cortex, basal forebrain system and hippocampus. The characteristic microscopic features 
of the disorder are the senile plaques (SPs), and the neurofibrillary tangles (NFTs) and 
vascular amyoid depositions (Selkoe, 1994). Additional features of AD are deficits in the 
multiple neurotransmitter signaling system and synaptic loss. 
One of the hypotheses concerning the cause of AD, the amyloid cascade 
hypothesis, which has been widely accepted states that the neurodegenerative process is a 
series of events triggered by the abnormal processing of the APP (Hardy and Higgins, 
1992) {Fig. 1). Accordingly, the major event leading to AD is the formation and 
aggregation in the brain of the amyloid P (AP) peptide, a proteolytically derived product of 
APP (Selkoe, 1994). 
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Fig. 2. Physiological and pathological cleavage of APP 
APP is cleaved sequentially by a- and y-secretases to produce a soluble version of APP (APPs-a), p3 and an 
83-residue COOH-terminal fragment (C83). Alternatively, APP can be cleaved by ¡3- and y-secretases to 
generate Af3, a soluble version of APP (APPs-f) and a 99-residue COOH-terminal fragment (C99). 
HBD: heparin-binding domain, KPI: Kunitz-type inhibitor domain (modified after Hardy and Selkoe, 2002) 
The Ap peptide is the predominant constituent of SPs and also deposits in cerebral blood 
vessels, leading to cerebrovascular dysfunctions (vascular hypothesis of AD; Kalaria, 
2002) (Glenner and Wong, 1984). 
APP is an evolutionarily conserved protein which is ubiquitously expressed in 
human cells including central nervous system (CNS) neurons (Kang et al., 1987). It is a 
type I integral membrane glycoprotein, with a long luminal N-terminal segment, a single 
membrane-spanning region and a short intracellular tail. Due to the alternative splicing of 
three exons (7, 8 and 15), APP exists as several different isoforms, the most common 
being APP695, APP751 and APP770 (Goldgaber et al., 1987). 
In the extracellular part of APP, binding domains for copper, zinc, heparin and 
collagen have been identified and the isoforms APP751 and APP770 also contain a KPI 
inhibitor domain (Kitaguchi et al., 1988). APP695, which lacks the KPI - insert, but 
contains a chondroitin sulfate glycosaminoglycan attachment site, is the splice product 
most common in neuronal cells (Kang et al., 1987). In the non-amyloidogenic processing 
pathway, the holo-APP is proteolytically processed by a-secretase, releasing the APPs-a 
and a membrane-bound C-terminal fragment (Fig. 2). a-Secretase cleaves within the Ap 
region, precluding the generation of Ap. The a-secretase activity has both constitutive and 
inducible components. The inducible a-secretase activity seems to be under the control of 
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second messenger cascades, such as protein kinase C (PKC) (Skovronsky et al., 2000). In 
the alternative, amyloidogenic pathway, cleavage in the transmembrane domain of APP by 
P-secretase (BACE) and an additional cleavage by y-secretase result in secretion of Ap. 
The proteolysis by y-secretase leads either to a 40 amino acid containing peptide (AP40) or 
a 42 amino acid containing isoform (AP42). The longer and more hydrophobic AP42 is 
much more prone to fibril formation than is AP40 and is the major Ap species in the SPs 
(Jarrett et al., 1993). 
1.3. The cholinergic hypothesis 
The cognitive deficits observed in AD are closely associated with losses in the 
cholinergic function of the brain, including a dramatic loss of choline-acetyltransferase 
activity (CAT, EC 2.3.1.6), acetylcholine (ACh) levels, the high-affinity choline uptake in 
the neocortex and hippocampus and a reduced number of cholinergic neurons in the basal 
forebrain and basal nucleus of Meynert (Cummings and Kaufer, 1996). As a 
neurotransmitter, ACh plays a critical role in learning and memory functions. It is 
synthesized from acetyl-CoA and choline by CAT and released into the synaptic cleft. 
Finally, it is degraded there by acetylcholinesterase (AChE, EC 3.1.1.7) into choline and 
acetic acid. Choline is taken up again into the presynaptic neurons for use in ACh 
synthesis (Fishman et al., 1986). BChE (EC 3.1.1.8), also known as pseudo- or non-
neuronal cholinesterase, is very similar in sequence, tertiary structure and function to 
AChE (Saxena et al., 1999). BChE is expressed in most human tissues and can be also 
found in the human amygdala, thalamus and hippocampal formation (Darvesh et al., 2003; 
Kálmán et al., 2004), yet its function is unknown. 
The AChE activity is reduced in AD overall (Fishman et al., 1986), though, it is 
increased in the SPs and NFTs in the early stages of the disease (Martzen et al., 1993). On 
the other hand, BChE activity in the brain increases with age over 60 years and it is further 
elevated in AD (Perry, 1980). It has been suggested that AChE may promote the 
aggregation of AP into a more toxic amyloid form (Munoz and Inestrosa, 1999). BChE is 
also associated with the SPs and NFTs and with amyloid angiopathy in AD (Mesulam and 
Geula, 1994). 
It has additionally been suggested that BChE may be involved in the lipid 
metabolism (Kutty and Payne, 1994) since elevated serum BChE activity has been found 
in type Ila, lib and IV hyperlipoproteinemias (Chu et al., 1978; Cucuianu et al., 1975; Jain 
et al., 1983). The results of animal experiments involving diabetic rats and mice, indicate 
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that BChE may have a role in the regulation of the lipoprotein metabolism (Kutty and 
Payne, 1994; Patel et al., 1990). It has further been reported that there is an association 
between the inheritance of apoE s4 and the extent of the cholinergic dysfunction in AD 
(Cedazo-Minguez and Cowburn, 2001). ApoE e4 allele carriers are reported to exhibit 
poorer responses to AChE inhibitors, as compared with apoE e2-3-positive subjects 
(Soininen et al., 1995). Consequently, impaired lipid delivery, especially of cholesterol, 
has been proposed as one mechanism for the apoE association to the cholinergic system 
(Poirier et al., 1995). 
1.4. The role of cholesterol in Afi peptide generation 
Cholesterol is an integral component of all eukaryotic cell membranes and is 
essential for normal cellular functions, including raft and caveola formation (Smart et al., 
1994). In these capacities, cholesterol is essential for life. However, an elevated 
concentration of plasma cholesterol is a well-established risk factor for CVD, and the 
emerging evidence suggests that the cholesterol metabolism plays a direct role in the 
pathogenesis of AD-(Sparks, 1997). 
Cholesterol also affects physical properties of cell membranes, such as increasing 
order and rigidity and decreasing permeability and lateral diffusion (Yeagle, 1991). The 
compartmentation of the APP molecule within the cell membrane is regulated by the 
cholesterol content of the bilayers (Kálmán and Janka, 2005). It has been hypothesized 
that APP is present in two cellular pools, one associated with lipid rafts, in which A(3 is 
generated, and another cholesterol-poor membrane domain outside the rafts, where a-
cleavage takes place (Simons et al., 1998). Hereby, the elevated cholesterol content of the 
cell membrane facilitates the (1- and y-cleavage of APP (Simons et al., 1998). Moreover, 
diet-induced hypercholesterolemia and atherosclerosis (AS) are both associated with (3-
amyloidosis in the transgenic (Tg) mouse model of AD (Li et al., 2003). Furthermore, 
there is evidence that cholesterol-lowering drugs can reduce the prevalence of human AD 
(Wolozin et al., 2000; Zandi et al., 2005) and beneficially interfere with the abnormal 
amyloid metabolism in Tg animal models of this type of dementia (Refolo et al., 2000). 
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Fig. 3. Schematic diagram showing the formation of atherogenic plaque 
IEL: internal elastic lamina, oxLDL: oxidized -low-density lipoprotein (modified after Xu, 2006) 
1.5 Common pathogenic factors in the formation of atherogenic plaque and Alzheimer's 
disease 
1.5.1. The roles of cholesterol and apoB-100 in the formation of atherogenic plaque 
In the periphery, apolipoprotein B-100 (apoB-100) is the major vehicle for 
cholesterol transport. It is synthesized in the liver and small intestine (Pitas et al., 1987). 
ApoB-100 is the key component in all classes of lipoproteins, including low density 
lipoprotein (LDL), intermediate-density lipoprotein and very low-density lipoprotein 
remnants considered to be atherogenic (Kim and Young, 1998). 
The key event in the development of atherogenic plaque is the formation of fatty 
streaks, i.e. the subendothelial accumulation of lipid-laden foam cells {Fig. 5). This 
process begins as the subendothelial retention of cholesterol-rich, atherogenic lipoproteins, 
LDL and its oxidation into oxLDL. Unsaturated fatty acids are rapidly oxidized to lipid 
hydroperoxides, which are converted during the decomposition phase to a variety of other 
products, including reactive aldehydes (e.g. malondialdehyde [MDA]) (Esterbauer et al., 
1987). Oxidatively modified LDL is rapidly taken up by macrophages. These aldehydes 
may react with lysine residues in the LDL apoB-100 moiety, resulting in a decreased 
affinity of apoB-100 for the LDL receptor and an increased affinity for scavenger 
receptors. This shift in receptor recognition leads to cellular uptake of the LDL by 
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receptors that are not regulated by the cholesterol content of the cell. The result is a 
massive accumulation of cholesterol in the macrophages and smooth muscle cells (SMCs). 
Such cholesterol-loaded cells have a foamy cytoplasm and develop the foam cells (Brown 
and Goldstein, 1990). 
1.5.2. The role ofplatelet APP in the formation of atherogenic plaque 
The A(3 and AP-like peptides are also present in human atherosclerotic plaques (De 
Meyer et al., 2002). The platelet phagocytosis that occurs within human atherosclerotic 
plaques can activate macrophages, and it has been suggested that the platelet constituent 
APP is involved (Jans et al., 2006). In vitro studies indicate that platelet phagocytosis also 
leads to macrophage activation and suggest that platelet-derived APP is proteolytically 
processed to Ap, resulting in inducible nitric oxide synthase induction. Accordingly, the 
hypothesis has been suggested that platelet phagocytosis evokes macrophage activation via 
the proteolytic processing of platelet-derived APP, similar to APP processing in microglia 
in brain tissue. Moreover, it has been shown that the messenger ribonucleic acid (mRNA) 
of BACE is also expressed in human atherosclerotic plaques and macrophages (De Meyer 
et al., 2002). This hypothesis represents a novel mechanism for macrophage activation and 
provides a biochemical link between AS and AD, as proposed in the vascular hypothesis 
of AD by Kalaria (1996) and Farkas (2001). 
1.5.3. Interaction between A/3 peptide and biglycan 
Several lines of evidence suggest roles for biglycan in AS and it is also probably 
involved in the pathogenesis of AD. Biglycan, member of the small leucine-rich protein 
family (Olin et al., 2001) is believed to be a critical molecule in the initiation of AS. The 
biglycan binds and retentions via ionic interactions of apoB in the LDL and may be 
especially important for extracellular lipid accumulation in the endothelium. In the brain, 
biglycan is present in the cytoplasm of the neurons, in the pia mater, in the ependyma and 
also in the tela choroidea vascular endothelial cells (Stichel et al., 1995). It has been 
suggested that extracellular matrix signaling molecules, such as heparan sulfate 
proteoglycans (HSPGs), regulate APP expression (Scholefield et al., 2003). Furthermore, 
APP has at least four heparin-binding domains (Clarris et al., 1997) and highly sulfated 
HSPGs may promote the amyloidogenic cleavage of APP (Leveugle et al., 1997). It was 
demonstrated earlier that biglycan is derived from endothelial cells and binds AP with low 
affinity (Snow et al., 1995). The selective affinity of vascular cell-derived biglycan and 
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other proteoglycans for AP may account for the accumulation of AP in conjunction with 
biglycan in cerebrovascular amyloid deposits in AD brain. 
1.6. Cholesterol homeostasis in the brain 
1.6.1. Brain cholesterol metabolism 
Cholesterol plays an essential role in the brain, eg. in synaptic plasticity (Koudinov 
and Koudinova, 2001), and optimal neurotransmitter release (Mauch et al., 2001; 
Yanagisawa, 2002). The CNS is unique as compared with other peripheral organs in 
regard of the cholesterol metabolism and cholesterol requirements (Dietschy and Turley, 
2001) for the following reasons: First, it accounts for only 2% of the entire body mass, but 
it is very rich in cholesterol: about 25% of the total amount of unesterified cholesterol in 
the entire body is contained in the CNS. Second, the brain is considered to be isolated 
from the blood and other organs by the blood-brain barrier (BBB). Cholesterol is 
synthesized de novo by a endoplasmic reticulum rate-limiting enzyme, 3-hydroxy-3-
methylglutaryl coenzyme A reductase (Brown et al., 1973), present in both the neuronal 
and glial cells. 
1.6.2. Association of apoE polymorphism and Alzheimer's disease 
In the normal brain, apoE is the principal cholesterol carrier protein; it is 
predominantly synthesized and secreted by astrocytes and microglia (Beffert et al., 1998). 
In humans, there are three common alleles of the apoE gene: e2, s3 and s4. The protein 
isoforms produced by these alleles differ in the amino acids at positions 112 and/or 158: e2 
(Cys 112, Cys 158), s3 (Cys 112, Arg 158), which is the most common, and s4 (Arg 112, 
Arg 158), which is present in at least one copy in ~25% of the population (Tanzi and 
Bertram, 2001). 
ApoE-mediated effluxes of cholesterol from both neurons and astrocytes have been shown 
to be isoform-dependent. Furtheremore, apoE s2 is the most, and s4 isoform is the least 
efficient at inducing cholesterol secretion (Michikawa et al., 2000). The binding of Ap is 
also isoform-specific: e2 > s3 > s4, thus permitting its aggregation and toxicity. In 
addition, both apoE s3 and s2 bind AP with higher affinities to facilitate clearance of the 
peptide following its release from the cells (Jordan et al., 1998). Accordingly, the 
polymorphism of the apoE protein, which plays roles in the redistribution of lipids and the 
control of cellular cholesterol homeostasis, is one of the major risk factors of AD. 
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Fig. 4. Schematic diagram showing the origin and distribution of the oxysterols in the human body, (modified 
after Reiss et al., 2004) 
1.6.3. Removal of cholesterol from the brain and its relationship to Alzheimer's disease 
Brain cholesterol is not removed via lipoproteins, but by conversion to 24-
hydroxycholesterol, a soluble oxysterol that can diffuse across the BBB (Fig. 4). The 
enzyme suggested to perform this conversion is cholesterol 24-hydroxylase (CYP46A1), a 
new subfamily member of the cytochrome P450 enzymes. CYP46A1 is highly expressed 
in the brain (Lund et al., 1999), mainly in neurons in the cerebral cortex, hippocampus, 
and dentate gyrus (Papassotiropoulos et al., 2002), the same neurons that are preferentially 
targeted in AD. In the circulation, 24(S)-hydroxysterol is cleared in the liver, by 
conversion into 7a-hydroxylated intermediates. In addition to its role in cholesterol efflux, 
24-hydroxycholesterol has a second potential role in the brain as it is a ligand for the 
nuclear hormone receptors liver X receptor, which are potent activators of several genes 
involved in the lipid metabolism (Bretillon et al., 2000). 
Furthermore, a single nucleotide polymorphism (SNP), thymine/ cytosine (T/C), in 
the intron of CYP46A1 gene (located on chromosome 14q32.1), has been reported to be 
associated with an increased amyloid load in the brain of AD patients, together with 
elevated tau and amyloid levels in the cerebrospinal fluid (CSF) (Papassotiropoulos et al., 
2003). In addition, Kölsch et al. (2002) found a C/T transition in intron 3, 43 base pairs 
upstream of exon 3 of CYP46A1. Carriers of the C allele of this polymorphism were more 
frequent in AD patients as compared with healthy controls, and carriers of the CC 
genotype had significantly higher 24-hydroxycholesterol/cholesterol ratios in the CSF than 
it 
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carriers of the CT and TT genotypes. One possible explanation for the effect of CYP46A1 
T/C polymorphism on the development of AD is the decreased activity of the enzyme 
expressed from the C variant of the gene, a subsequent increase in the cholesterol content 
of neuronal membranes leading to a shift to the amyloidogenic p-cleavage of the APP 
(Kálmán et al., 2004; Simons et al., 2001). The interaction of the CYP T/C SNP with the 
s4 allele of the apoE gene has been proposed as a combined risk factor for AD (Wang et 
al., 2004). 
1.7. Hypercholesterolemia and atherosclerosis. The Alzheimer's disease connection 
Vascular risk factors, such as an elevated serum cholesterol level and hypertension, 
are shared risk factors for both AD, vascular dementia (VD) and AS (Engelberg, 2004). 
Moreover, VD frequently overlaps with primary neurodegenerative diseases, such as AD. 
The common cause of cognitive impairment and dementia is a chronically reduced blood 
supply to the brain, generally resulting from cerebral AS. In the circulation, the blood 
platelets are the major sources of APP and AP peptide released into the blood, which may 
trigger the key pathological events in AD pathogenesis (Chen et al., 1995). The AP 
peptides often form deposits in the walls of the cerebral capillaries, arterioles and arteries 
of AD patients, leading to cerebral amyloid angiopathy and, in some, hemorrhagic stroke 
(Ghiso and Frangione, 2001). 
The main risk factors for AS are the high levels of both apoB-100 and LDL 
cholesterol in the plasma (Sniderman et al., 1980). The LDL cholesterol and apoB-100 
levels are also increased in AD and correlate with the amount of AP deposited in the brain 
(Caramelli et al., 1999). In the normal brain, apoE and apolipoprotein A-I are the most 
abundant lipoproteins, with less apolipoprotein J (Raffai and Weisgraber, 2003) and a very 
limited amount of apoB (Pitas et al., 1987). In contrast, abnormal levels of apoB-100 and 
cholesterol accumulate in the brain of AD patients and have been found as core 
components of the mature plaques (Houlden et al., 1995; Mori et al., 2001; Puglielli et al., 
2003). This discrepancy may be due to the disruption of the BBB which occurs in a 
number of pathological conditions, including stroke (Hulthe et al., 1997) and possibly AD 
(Skoog et al., 1998). Accordingly, these results suggested that AS involving 
hypercholesterolemia influences the risk of development of AD. 
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1.8. High-cholesterol diet and transgenic mouse model of atherosclerosis 
Numerous animal species have been used to study the pathogenesis and potential 
treatment of the lesions of AS (Jawien et ah, 2004). The most useful models have been 
restricted to relatively large animals, such as nonhuman primates, swine and rabbits 
(Drobnik et ah, 2000). Rats and dogs are not good models for AS because they do not 
develop spontaneous lesions and require heavy modifications of the diet to produce 
vascular lesion (Drobnik et ah, 2000). In recent years, in the number of in vivo studies 
used Tg mouse models to study atherogenic mechanisms because the mouse as a model 
supremely suffices for as criteria (Breslow, 1996). Furthermore, uniquely in mice, it is 
possible to knock out or replace endogenous genes; this is one of the main advantages of 
working with the mouse model. 
Accordingly, in our experimental design, Tg mouse lines overexpressing the 
human apoB-100 and biglycan genes were generated. Among the inbred mouse strains, the 
strain C57B6 has been found to be the most susceptible to the development of AS lesions 
upon administration of a high-cholesterol (HC) diet (Jawien et ah, 2004). Therefore, the 
apoB-100 Tg mice backcrossed twice with the C57/B6 x CBA strain was used in our 
studies. 
On the other hand, it is important to acknowledge that many noteworthy 
differences exist between mice and humans. The serum lipid profile in mice is very 
different from that in humans. These rodents carry most of the cholesterol on high-density 
lipoprotein (HDL). Furtheremore, since they have low LDL cholesterol levels, they are 
protected against hypercholesterolemia and do not develop AS without dietary or genetic 
manipulations (Breslow, 1996). The human apoB-100 Tg mice has mildly increased LDL 
and total cholesterol (TC) levels, as confirmed by FPLC analysis, their lipoprotein profile 
showing a distinct LDL peak, in contrast with wild-type (Wt) mice, which have only a 
distinct HDL (Voyiaziakis et al., 1998). These mice also furnish a very diet-responsive AS 
model. AS is not observed when the mice are on a regular diet, but it develops in response 
to feeding with either the HC-diet or a western-type diet (Purcell-Huynh et ah, 1995). This 
mouse model permits study of the APP metabolism due to the presence of the human 
apoB-100, which results in a "human-like" lipoprotein profile (Grass et ah, 1995). 
1.9. Serum and brain cholesterol. Possible connections 
Several studies with various animal models, such as rabbits, guinea-pigs and A0-
depositing Tg mice, have provided further evidence that changes in peripheral cholesterol 
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metabolism modulate the APP processing in brain, possibly as a result of alterations in the 
brain cholesterol content (Fassbender et al., 2001; Howland et al., 1998; Petanceska et al., 
2002; Refolo et ah, 2000; Refolo et ah, 2001; Shie et ah, 2002; Sparks, 1996). 
Accordingly, it has been demonstrated that hypercholesterolemia results in a significant 
increase in the accumulation of A0 in double PSAPP Tg mice (Refolo et ah, 2000). 
Treatment of Tg mice exhibiting an AD Ap phenotype with the cholesterol-lowering drug 
BM15.766 results in hypocholesterolemia associated with reduced AP accumulation 
(Refolo et ah, 2001). Furthermore, clinical and epidemiological studies have indicated that 
patients with elevated cholesterols level have an increased susceptibility to AD (Jarvik et 
ah, 1994) and that the incidence of AD is higher in countries with HC and high-calorie 
diets (Kalmijn et ah, 1997). Accordingly, in our studies we set out to prove that the 
alterations in the peripheral cholesterol influence the brain APP metabolism. 
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2. Aims 
The aims of our studies were: 
1. 1.1. To examine whether a HC diet affects the serum TC, LDL cholesterol and 
MDA levels in Wt and Tg (apoB+/+) mice. 
1.2. To investigate how a HC diet and human apoB-100 gene overexpression, 
either individually or in combination, affect the brain APP metabolism in 
Tg mice. 
1.3. To examine whether human biglycan gene overexpression can affect the 
brain APP metabolism in Tg mice. 
1.4. To explore whether the individual and combined effects of a HC diet and 
overexpression of the human apoB-100 and biglycan genes modulate the 
brain APP metabolism in the double Tg mouse model. 
1.5. To investigate whether the individual and combined effects of a HC diet or 
human apoB-100 and biglycan interact with the brain BACE and PKC 
levels in Tg mice. 
2. To study whether a HC diet and overexpression of the human apoB-100 and 
biglycan genes influence the activity of two major ACh-degrading ezymes 
of the cholinergic system, AChE and BChE, in the serum, liver and brain of 
Tg animals. 
3. 3.1. To examine whether inheritance of the CYP46 C allele is associated with 
AD in a Hungarian cohort. 
3.2. To determine whether an interaction exists between the apoE s4 and CYP46 
C alleles in this Hungarian population. 
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3. Materials and methods 
3.1. Materials 
The substances used in this study were (listed in alphabetical order): l,5-bis(N-
allyl-N,N-dimethyl-4-ammoniumphenyl)- pentan-3-one dibromide (BW 284C51) from 
Wellcome Research Labs (Beckenham, UK); anti-Alzheimer precursor protein A4 (Mab 
22C11), anti-protein kinase C (anti-PKC) and -P-secretase (anti-BACE) polyclonal 
antibody from Chemicon International Inc. (Temecula, CA, USA); BioMax light 
autoradiographic film from Sigma-Aldrich (St Louis, MO, USA); Cfol from Sigma-
Aldrich Ltd. (Poole, UK); cholesterol colorimetric assays from Diagnosticum Ltd. 
(Budapest, Hungary); ethopropazine from Wellcome Research Labs (Beckenham, UK); 
ethylenediaminetetraacetic acid (EDTA) from Sigma-Aldrich (St Louis, MO, USA); 
GeneStormR Expression-Ready clone expressing the human biglycan gene from 
Invitrogen (Carlsbad, CA); HMW-SDS marker kit from Amersham Pharmacia Biotech 
(Uppsala, Sweden); horseradish peroxidase (HRP)-conjugated anti-mouse IgG and HRP-
conjugated anti-rabbit IgG from Jackson ImmunoResearch Laboratories Inc. (West Grove, 
PA, USA); Hybond ECL nitrocellulose membrane from Amersham Pharmacia Biotech 
(Uppsala, Sweden); leupeptin from Sigma-Aldrich (St Louis, MO, USA); Mspl Gibco 
BRL (Paisley, UK); pepstatin A, phenylmethylsulfonyl fluoride (PMSF) from Sigma-
Aldrich (St Louis, MO, USA); protease K solution from Boehringer Mannheim 
(Indianapolis, IN, USA); Ready-to-Go kit was from Pharmacia (Uppsala, Sweden); Rotor-
Gene 2000 from Corbett Research (Sydney, Australia); ribonuclease (Rnase) from Sigma-
Aldrich (St Louis, MO, USA); sodium dodecylsulfate (SDS) from Merck (Darmstadt, 
Germany); Standard Lipid Controls from Sentinel (Milano, Italy); Supersignal® West Pico 
Chemiluminescent Substrate from Pierce (Rockford, IL, USA); Taq DNA polymerase 
from Fermentas (St Leon-Rot, Germany); [a-32P]deoxycytidine-5-triphosphate (dCTP) 
was from Izotop Ltd. (Budapest, Hungary); RevertAid™ First Strand cDNA Synthesis Kit 
from Fermentas (St Leon-Rot, Germany); Trizol reagent from Sigma-Aldrich (St Louis, 
MO, USA); Tween 20 from ICN Biomedicals (Eschwege, Germany); all other reagents 
were commercial products of analytical grade with the highest purity available. 
3.2. Subjects 
125 AD patients (46 males and 79 females; mean age 74.4 years; standard 
deviation (SD): 6.38 years) who met the National Institute of Neurological and 
Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders 
Association (McKhann et al., 1984) and Diagnostic and Statistical Mannual of Mental 
Disorders 4th edition criteria for probable AD and 102 age- and sex-matched controls 
(CNT) (45 males and 57 females; mean age 73.5 years; SD 5.28 years) were enrolled in 
the study. The AD probands had late-onset (over the age of 65 years) sporadic type of AD. 
Their Mini-Mental State Examination (MMSE) (Folstein et al., 1975) scores were 17.3 ± 
5.43 points (mean ± SD). The CNT group had significantly 0=0.0001) higher MMSE 
scores, (28.3 ± 1.01 points, mean ± SD). All subjects were Hungarian and Caucasian. All 
venous blood samples for genotyping were obtained in accordance with the written 
informed consent procedures approved by the local ethics committee (Institutional Review 
Board of the University). 
3.3. Transgenic animals and diet 
Fertilized oocytes from Wt female mice (C57/B6 x CBA F l ) were collected and 
injected with purified Pl-phagemid deoxyribonucleic acid (DNA) containing the entire 43 
kb human apoB-100 gene in a concentration of 1 ng/ml and a GeneStormR Expression-
Ready clone expressing the human biglycan gene in a concentration of 2 ng/pl, using the 
standard pronucleus microinjection technique (Hogan et al., 1996). This GeneStormR 
Expression-Ready clone construct involves human biglycan cDNA fused to a 
cytomegalovirus promoter, a V5 epitope and a 6X His Tag sequence at the 3' end of the 
cDNA. A 3440 bp fragment including the transcription unit was separated from the vector 
backbone. 
Microinjected eggs were implanted into the oviduct of pseudopregnant Swiss 
female mice. Tg founders were identified by using polymerase chain reaction (PCR) 
analysis and dot blot hybridization on tail DNA samples. The apoB-100 Tg mice and the 
biglycan Tg mice were homozygous for the human apoB-100 and biglycan transgene. The 
primers for PCR analysis are shown in Table 1. For dot blot hybridization, a 824 bp, Nru 
I-Hind III fragment was labeled with [a-32P] dCTP and hybridized to 5 pg of genomic 
DNA. All animal experiments were performed in accordance with institutional guidelines. 
Transgene expression from different tissues (liver, brain, heart and muscle) of Tg 
mice was tested by using quantitative reverse transcriptase PCR (QRT-PCR) and in the 
case of Tg apoB-100 the clone 485 and in the case of Tg biglycan the clone 1052, which 
expressed the human apoB-100 or the biglycan mRNA at the highest level, was selected 
for further study. 
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Table 1. Primers for RT-PCR and QRT-PCR 
Targets for 
RT-PCR 
Forward primer Reverse primer 
Expected 
size (bp) Reference 
APP695 
5' -GC ACT A ACTTGC ACG-
ACTATGGCATGCTGCTG-
CCCTG-3', 500-537 bp 
5'-
GCTGGCTGCCGTCGTGG-
GAACTCGGACTACCTCCT-
CCACA-3', 861-901 bp 
242 
APP770 5'-CTACCACTGAGTCT-GTGGAG-3', 848-868 bp 
5'-
CTTGAGTAAACTTTGGG-
ATGACACGCTGCCACAC-
ACCGCC-3', 1028-1068 bp 
401 
(Shivers et al., 
1988; Kang et 
al., 1987, Sola 
et al., 1993) 
ß-actin 5' -GTGGGCCGCTCTA-
GGCACAA-3', 25-45 bp 
5' -CTCTTTG ATGTC ACGC A-
CGATTTC-3', 564-540 bp 
537 
apoE 
5'-TCCAAGGAGCTGCA-
GGCGGCGCA-3' 
5'-ACAGAATTCGCCCCGG-
CCTGGTAC ACTGCC A-3' 217 
(Crook et al., 
1994) 
CYP46A1 5-TGA AAA CGA GTTTCC- CGT CC-3' 
5-GTG TGA CCA GGT AA-
CAGT CA-3' 
285 (Borroni et al., 
2004) 
Targets for 
QRT-PCR 
apoB-100 5'-CCCAAGAGGTATTTAA-
AGCCATT-3' 
5'-
CGTAGCACCTCTGTGGT-
CTTG-3' 
biglycan 5'-GGA CTC TGT CAC 
ACC- CAC CT-3' 
5'-AGC TCG GAG 
ATGTCG- TTGTT- 3' 
Designed by 
our group. 
ß-actin 5'-CCAGCAGATGTGGATC-
AGCA-3' 
5'-CTTGCGGTGCACGAT-
GG-3' 
Homozygous apoB-100 (apoB+/+) and biglycan (bg+/+) Tg mice were crossed in order to 
obtain hemizygous double Tg (apoB+/" x bg+/") littermates. Both the Wt F1 and the Tg F1 
generation mouse lines were backcrossed twice with the C57B6 strain in order to approach 
closer to the susceptible genetic background. The 6-week-old Wt, Tg (apoB+/+) and double 
Tg (apoB , bg+/") mice were fed with a standard laboratory diet supplemented or not with 
2% cholesterol (5 mice/group) for 17 weeks under standard laboratory conditions (Csont et 
al., 2002). Accordingly, we used seven animal groups: Wt, apoB-100 Tg [Tg (apoB+/+)], 
biglycan Tg [Tg (bg+/+)], apoB-100, biglycan Tg [Tg (apoB+/+, bg+/+)] mice and their 
matches with a HC diet: HC Wt, HC Tg (apoB+/+) and HC Tg (apoB+/+, bg+/+). The 
animals were anesthetized after the treatment period and blood samples were obtained 
intracardially. Brains were removed without perfusion and the whole cerebral cortex was 
isolated and stored at -70 °C until used. The experimental protocol was approved by the 
local animal care ethical committee. 
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3.4. Selection of the transgenic apoB-100 and biglycan mouse lines 
The apoB-100 gene was detected by means of QRT-PCR, and the mouse P-actin 
gene was applied as an internal control. One Tg line (No. 485) exhibited a very high 
expression of human apoB-100 transgene (arbitrary rate: 0.78-fold) in the liver. In the case 
of biglycan, the clone 1052 expressed a very high amount of the human biglycan gene. 
These Tg mouse lines (No. 485 and No. 1052) were therefore used to generate the double 
Tg (apoB+/~ x bg +/") mice. 
3.5. DNA extraction from white blood cells 
DNA was isolated from the white blood cells by using the anticoagulated, EDTA-
treated whole blood samples. The blood samples were stored at -70 °C. Frozen samples 
were thawed at 4 °C, incubated with a 10-fold volume of lysis buffer (10 mM Tris-HCl, 
400 mM NaCl and 2 mM Na2EDTA, pH 8.2) at 4 °C for 5 min and centrifuged at 15 000 x 
g for 20 min. After removal of the supernatant, the pellet was washed twice with 
phosphate-buffered saline (PBS, pH 7.4) and centrifuged at 5 000 x g for 10 min at 4 °C. 
The cell lysates were digested overnight at 55 °C with 0.2 ml of 10% SDS and 0.5 ml of a 
protease K solution (1 mg protease K in 1% SDS and 2 mM Na2EDTA). After digestion 
was complete, the resuspensed pellet was extracted with equal volumes of phenol by 
vigorous shaking for 5 min, and centrifugation at 6 000 x g for 10 min at 4 °C. The 
precipitated protein pellet was discardedand the supernatant was extracted twice with equal 
volumes of chloroform-isoamyl alcohol (24:1) by vigorously shaking for 5 min and 
centrifuged at 6 000 x g for 10 min at 4 °C. To the aqueous supernatant, was added one-
tenth volume of 3.0 M sodium acetate, and the DNA was precipitated with ethanol at -20 
°C with inversion of several times. The precipitated DNA strands were removed with a 
glass pipet and were washed once with 70% alcohol. The DNA pellet was resuspended in 
Trishydrochloride buffer (containing 10 mM Tris-HCl, 0.2 mM Na2EDTA, pH 7.5). The 
DNA was allowed to dissolve for 2 h at 37 °C, followed by digestion with a 100-fold 
volume of RNase (1000 pg/ml). The concentration was determined by ultraviolet 
spectrophotometry. 
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3.6. ApoE and CYP46 genotyping 
3.6.1. ApoE genotyping 
The apoE genotyping were determined by PCR from genomic DNA with the 
specific primers (Table 1). The final volume of PCR solution was 25 pi, containing 20 pM 
of two primers, 1.25 pi of each, 50-300 ng of genomic DNA, 1.25 pi of deoxynucleoside 
triphosphates (dNTPs) (20 mM), consisting of a mix of 5 mM of each, 1.5 pi (25 mM) of 
MgCh, 2.5 pi (5%) of dimethyl sulfoxide, and 0.5 U of Taq DNA polymerase, in 67 mM 
Tris-HCl buffer (pH 8.8). The initial denaturation was 5 min at 95 °C, followed by 30 
cycles of 30 s at 94 °C denaturation, 22 s at 63 °C, and annealing and extension for 30 s at 
72 °C. A final extension for 3 min at 72 °C completed the amplification procedure. The 
amplified DNA was digested with 5 U of Cfo\ overnight at 37 °C, and the DNA fragments 
(91, 81, 72 and 48 base pairs) were separated on 8% non-denaturing acrylamide gel. The 
gel was stained with 0.5 pg/ml of the ethidium bromide, and the apoE genotype was 
determined by the pattern of DNA fragments presented. 
3.6.2. CYP46genotyping 
The 285 bp PCR product containing CYP46A1 was determined by PCR from 100 
ng of genomic DNA with the specific primers (Table 1). 
The final volume of PCR solution was 25 pi, containing 0.2 pM of the two primers, 
1 pi of each, 0.25 pi of dNTPs (200 pM), consisting of a mix of 5 mM of each, 1.5 pi of 
(25 mM) MgCl2, and 0.2 pi of Taq DNA polymerase (1 U), in 67 mM Tris-HCl buffer (pH 
8.8). After the initial denaturation at 95 °C for 5 min, the reaction mixture was subjected to 
32 cycles of 30 s denaturation at 95 °C, 30 s annealing at 53 °C, and 30 s extension at 72 
°C, followed by a 10 min extension step at 72 °C. Amplified products were digested by 
Mspl restriction enzyme. A 209 bp and a 76 bp fragments were recognized as C, while the 
285 bp undigested product corresponded to the T allele, respectively. The results of 
amplification and the digestion fragments were revealed by 2% and 3% agarose gels with 
0.5 pg/ml of ethidium bromide, respectively. 
3.7. Determination of serum lipid and cholesterol levels in Wt and Tg (apoB+/+) mice 
Blood samples of Tg mice were obtained intracardially and the serum lipids, TC 
and LDL cholesterol levels were measured in triplicate, using commercially available 
colorimetric assays adapted to a 96-well plate kit. LDL cholesterol was determined 
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following the selective protection of LDL. The accuracy of the assays was monitored by 
using standard lipid controls. Results are expressed as mM/1 of serum. 
3.8. Measurement of serum malondialdehyde levels in Wt and Tg (apoB+/+) mice 
Thiobarbituric acid (TBA)-reactive substances (TBARS) were assayed in order to 
measure the level of lipid peroxidation (Buege and Aust, 1978). Serum samples were 
mixed with 2 volumes of a stock solution of 15% w/v trichloroacetic acid, 0.375% w/v 
TBA and 0.25 M HC1, heated for 30 min at 95 °C. After cooling and centrifugation at 
1000 x g for 10 min, the supernatants containing TBARS were measured 
spectrophotometrically at 535 nm. Freshly diluted tetramethoxypropane, which yields 
MDA, was used as external standard. Results are expressed as nmol MDA/ml serum. 
3.9. Measurement of AChE and BChE activities in the serum, liver and brain of Wt and 
Tg (apoB+/+) mice 
AChE and BChE activities were determined by spectrophotometric assay (Ellman 
et al., 1961). BW 284C51 (10"5 M) and ethopropazine (10"4M) were used as specific AChE 
and BChE inhibitors, respectively. Each sample was measured in triplicate, with an intra-
assay variation of less than 10%. Protein was measured by the dye-binding assay of 
Bradford (1976). The enzyme activities are expressed as nmol substrate 
hydrolyzed/min/mg protein. 
3.10. Quantitation of brain APP mRNAs by the reverse transcriptase polymerase chain 
reaction 
Total cellular ribonucleic acid (RNA) was extracted from the brain cortex of Wt 
and Tg mice with the guanidium thiocyanate phenol/chloroform method (Chomczynski 
and Sacchi, 1987). Five pg of total mRNA was transcribed into cDNA with oligo (dt)ig 
primers. The cDNA was amplified by PCR with oligonucleotides for (3-actin, APP770 and 
APP695 (539, 401 and 242 bp of PCR products, respectively). Primer sequences are 
shown in Table 1. Reactions were performed with a My Cycler™ Thermal Cycler. PCR 
was carried out in a final volume of 25 pi, containing 2.5 pi of lOx PCR buffer, 2 pi of 25 
mM MgCE, 4 pi of 5 mM dNTP, 3 pmol of primers specific for P-actin and APP695, and 
10 pmol of primers for APP770, 2 pi of the template cDNAs described above and 0.25 pi 
of Taq DNA polymerase (5 units/pl). Thirty cycles consisted of denaturation (30 s at 95 
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°C), annealing (30 s at 55 °C) and extension (1 min at 72 °C). PCR products were 
separated by 1.3% agarose gel electrophoresis. The ratios APP695/p-actin and APP770/P-
actin mRNA were calculated. 
3.11. Quantitation of human apoB-100 and biglycan mRNAs by the real-time reverse 
transcriptase polymerase chain reaction 
The expression of the human apoB-100 and the human biglycan transgenes were 
detected by using QRT-PCR. The total RNA from the liver of Tg mice was purified with 
Trizol reagent and reverse transcribed (RevertAid™ First Strand cDNA Synthesis Kit). 
Primer sequences for QRT-PCR are shown in Table 1. PCR reactions were run on a Rotor-
Gene 2000, using the green dye SYBR to detect double-stranded products. Curves were 
analyzed with Rotor-Gene software, using dynamic tube and slope correction methods, 
data from cycles close to the baseline being ignored. Relative expression ratios were 
normalized to P-actin. The analysis of the results was performed by the Pfaffl method 
(Pfaffl, 2001). 
3.12. Sample preparation for Western blotting 
For APP and PKC detection, five cortices of Wt and Tg mice from each group 
were homogenized in 50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl, 2 mM PMSF, 
2 mM EDTA, 2 pg/ml of leupeptin and 1 fig/ml of pepstatin by using a glass-teflon potter 
(1500 rpm, 1 min). The cortical homogenates were centrifuged at 100 000 x g for 30 min 
at 4 °C. The supernatant represented the soluble fraction, while the pellet was resuspended 
in the same volume of buffer containing 1% SDS and centrifuged as before. The new 
supernatant represented the membrane fraction. 
For BACE level measurement, the soluble and membrane-bound fractions were not 
separated. Cortices were homogenized in 50 mM Tris buffer pH 7.5 containing 0.15 M 
NaCl, 2 mM PMSF, 2 mM EDTA, 2 pg/ml of leupeptin, 1 pg/ml of pepstatin and 1% 
SDS. The homogenates were centrifuged at 10 000 x g for 30 min at 4 °C. The 
supernatants were used for protein assay (Hess et al., 1978) 
3.13. Western blotting 
The cortical protein samples were loaded onto 9% SDS-polyacrylamide gels. After 
the electrophoresis, proteins were electrotransferred to nitrocellulose membranes by using 
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the BioRad Mini Protean II System. Blocking was carried out with Tris-buffered saline 
containing 0.02% Tween 20 (TBST) supplemented with 5% non-fat dry milk solution. For 
the labeling of APP, PKC and BACE, monoclonal 22C11 antibody (5 pg/ml; against 
residues 68-81 of APP), monoclonal PKC antibody (1:2000) and BACE polyclonal 
antibody (1:1000) were applied. After three washes with TBST, sheep anti-mouse IgG-
HRP (1:1000), or goat anti-rabbit IgG-HRP (1:5000) was added for 1 h. The nitrocellulose 
membrane was washed again three times with TBST. In the cases of APP, PKC and 
BACE, the bands were detected with the Supersignal® West Pico Chemiluminescent 
Substrate and then exposed to Kodak autography film. The optical densities (ODs) of 
immunoreactive bands were quantified by means of the National Institutes of Health 
Image Analyzer System. 
3.14. Statistical analysis 
Data are expressed as means ± standard error of the mean (SEM). Results were 
considered to be significantly different at a probability level of/?<0.05. 
The Western blotting, RT-PCR, serum lipid, MDA levels, and AChE and BChE activity 
values of the examined groups were compared by one-way analysis of variance 
(ANOVA), with the Sidak probe for pairwise comparisons. 
The differences between the mean age and MMSE values of the AD probands were 
tested by the Mann-Whitney U test. Hardy-Weinberg equilibrium of the examined genes 
was calculated by the chi square (x2) test. Gender differences and allele frequencies were 
compared with the Pearson x2 test. In the case of tables with small-expected frequencies, p-
values were also computed by using exact methods (i.e. Fisher's test for 2 x 2 tables). The 
X test was used to determine whether gender is associated with the CYP46A1 T/C SNP. 
Odds ratios (ORs) as estimates of the relative risk of disease were calculated according to 
the Wilson formula (Wilson, 1927) for the 95% confidence intervals (CIs) of the 
percentages of CYP46 C/T genotypes and alleles. A logistic regression model was used to 
test for the interaction between the CYP46 C and apoE s4 alleles. 
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4. Results 
4.1. Serum lipid and TC levels in the Wt and Tg (apoB+/+) mice 
The HC Tg (apoB+/+) animals had a significantly higher serum TC level (4.8 ±0 .17 
mM/1) as compared with the Wt, the Tg (apoB+/+) and the HC Wt groups (3.1 ± 0.17 
mM/1,/?=0.047, 3.2 ± 0.44 mM/1, /?=0.048, and 3.1 ± 0.32 mM/1, /?=0.049, respectively). 
The serum TC and LDL levels were not altered in the HC Wt mice as compared with the 
normal diet-fed Wt animals. The HC diet significantly increased the serum concentration 
of atherogenic LDL cholesterol in the HC Tg (apoB+/+) mice (2.3 ± 0.29 mM/1) as 
compared with the Wt, the Tg (apoB+/+) and the HC Wt groups (1.1 ± 0.14 mM/1,/?=0.004, 
1.2 SEM ±0.15 mM/1, /?=0.019 and 1.5 ± 0.05 mM/l,/?=0.05, respectively). 
4.2. Serum malondialdehyde levels in Wt and Tg (apoB+/+) mice 
The MDA levels were significantly higher in the HC Wt (45.6 ±1.5; /?=0.006) and 
in the HC Tg (apoB+/+) (48.2 ± 2.2; /?=0.006) mouse groups than in the Wt group (34.2 ± 
3.02,^=0.008). The MDA level was not altered in the Tg (apoB+/+) animals (39.8 ± 3.2,/?= 
0.34). 
Table 2. Effect of HC diet on serum, liver and brain AChE and BChE activities in the Wt, Tg (apoB+/+), Tg 
(bg+/+) and Tg (apoB+/~, bg'j Tg mice 
Wt Tg(apoB+ / +) Tg(bg+ / + ) Tg (apoB+/\ HC diet-fed H C diet-fed HC diet-fed 
bg+ /) Wt Tg (apoB+/+) Tg(apoB + / - ,bg + / ) 
(n=5) (n=5) (n=5) (n =5) (n=5) (n=5) (n=5) 
Serum 
AChE 5.11±0.9 2.75±0.1 2.84±0.2 5.09±0.9 6.24±0.8 2.63±0.2 5.31±0.8 
BChE 55.4±1.5 49.3±1.8 52.0±2.2 46.8±3.7 58.4±1.1 48.8±2.4 52.6±5.2 
Liver 
AChE 0.70±0.1 0.94±0.6 0.93±0.6 0.62±0.6 0.90±0.1 0.88±0,1 0.55±0.9 
BChE 15.0±0.6 19.1±0.8* 17.6±1.6 14.1±0.8 15.6±0.4 17.0±1.2 15.5±0.4 
Brain 
AChE 165.0±1.4 153.7±2.6 151.5±2.9 166.9±2.7 157.9±1.3 165.4±5,7 168.9±5.2 
BChE 1.04±0.1 0.97±.03 1.03±0.9 0.90±0.2 0.97±0.1 0.85±0.8 0.80±0.7 
AChE and BChE activities were expressed in nmol/min/mg protein. The values are expressed as means + 
SEM. Asterisks (*) indicatep<0.05. 
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Fig. 5. APP/p-actin ratios in the normal diet-fed Wt, HC Wt, the Tg (apoB j and the HC Tg (apoB j 
mice. The ratios of OD values are expressed as means ±SEM (n=5). Asterisks (*) indicate p<0.05. 
4.3. Effects of HC diet on ACItE and BCItE activities in the serum, liver and brain of 
Wt and Tg (apoB+/+) mice 
The BChE activity was significantly increased in the liver the Tg (apoB+/+) group 
(19.1 ± 0.98 nmol/min/mg protein) as compared with the Wt group (16.0 ± 0.46 
nmol/min/mg protein, /?<0025) (Table I). We did not find any other statistically significant 
differences between the different groups as concerns other examined tissues. 
4.4. Effect of HC diet on the cortical APP metabolism 
The HC diet significantly increased the APP695 (123%, p=0.027) and APP770 (138%, 
p=0.042) mRNA levels in the cortex as compared with the Wt animals (Fig. 5). The HC 
diet decreased the APP levels in the soluble fraction (87%, /?=0.006) in the Wt animals, 
while the membrane-bound APP levels increased significantly (114%, /?=0.036) (Fig. 
7). 
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Fig. 6. APP/[Factin ratios in the Tg (bg '), the Tg (apoB bg ') and the HC Tg (apoB bg'') mice. The 
ratios of OD values are expressed as means ± SEM (n=5). Asterisks (*) indicate p<0.05. 
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Fig. 8. OD values of the APP isoforms in the APPsol and the APPmembr fractions. Semiquantitative 
evaluation of the Western blots of the Tg (bg ), the Tg (apoB ,bg ) and the HC Tg (apoB ,'bg ') mice. 
Values are expressed as means ±SEM (n=5). Asterisks (*) indicate p<0.05 as compared with the Wt group. 
4.7. Combined effect of the human apoB-100 and biglycan transgenes on the cortical 
APP metabolism 
The APP695 mRNA levels were not altered in the cortex of the double Tg (apoB+/\ bg^ ") 
mice relative to the Wt animals (Fig. 6). A slight, statistically not significant increase in 
the level of APP770 mRNA could be observed in the cortex of the Tg (apoB+/", bg+") mice 
as compared with the Wt animals (Fig. 6). Quantitative analysis of immunoblots 
demonstrated that the membrane-bound APP isoforms in the membrane-bound fraction 
were significantly increased (122%, /?=0.035) in the Tg (apoB+/~, bgf/") mice as compared 
with the Wt mice (Fig. 8). No differences were found in the soluble fraction of the cortex 
of the Tg (apoB+/\ bg+/') mice (Fig. 8). 
4.8. Combined effect of HC diet with the human apoB-100 transgene on the cortical 
APP metabolism 
The common effect of the HC diet and the overexpression of apoB-100 did not 
significantly alter the cortical APP695 and APP770 mRNA levels in any of the studied 
groups (Fig. 5). Quantitative analysis of the Western blots demonstrated that the HC diet 
significantly increased (171%,/?=0.0001) the levels of the membrane-bound APP isoforms 
in the HC Tg (apoB+/+) animals relative to the Tg (apoB +) group. In the HC Tg (apoB+/+) 
mice, the membrane-bound APP isoforms were also increase (134%, /?=0.004) relative to 
the Wt controls (Fig. 7). 
31 
• A P P s o l 
• APPmerabr 
Wl HC YVt Tg (apoB+/+) HC Tg 
(apoB+/+) 
Fig.7. OD values of the APP isoforms in the soluble (APPsol) and the membrane-bound (APPmembr) 
fractions. Semiquantitative evaluation of the Western blots of the Wt, the HC Wt, the Tg (apoB j and the 
HC Tg (apoB mice. Values are expressed as means ± SEM (n=5). Asterisks (*) indicate p<0.05 as 
compared with the Wt group; the square (m) indicates p<0.05 as compared with the Tg (apoB j group; and 
the triangle (A) indicates p<0.05 as compared with the HC Wt group. 
4.5. Effect of the human apoB-100 transgene on the cortical APP metabolism 
We did not observe significant differences in the levels of the mRNA isoforms in 
the cortex of the Tg (apoB / +) mice as compared with the Wt animals (Fig. 5). The levels 
of the membrane-bound APP isoforms were significantly decreased in the Tg(apoB ) 
animals (78%, /?=0.005) relative to the Wt group (Fig. 7). The APP levels in the soluble 
fraction of the cortex were not altered in the Tg (apoB+/+) mice (Fig. 7). 
4.6. Effect of the human biglycan transgene on the cortical APP metabolism 
Significantly increased APP695 mRNA isoform levels (122%, p=0.012) were 
observed in the cortex of the Tg (bg+/+) mice as compared with the Wt animals (Fig. 6). 
The extent of the increase in the APP770 mRNA level was much higher, since the 
biglycan transgene caused a 1.5-fold elevation (p=0.0001) relative to the control value 
(Fig. 6). No significant changes were found in the APP isoforms in either the soluble or 
the membrane-bound fraction in the cortices of the Tg (bg+/+) mice (Fig. 8). 
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However, the HC diet did not have a significant effect on the levels of the APP 
isoforms in the soluble fraction of the cortices of the HC Tg (apoB+/+) group as compared 
with those in the Tg (apoB+/+) mouse and the Wt mouse group (Fig. 7). 
4.9. Combined effect of HC diet, and the human apoB-100 and biglycan transgenes on 
the cortical APP metabolism 
The APP695 isoforms were significantly (125%, p=0,002) increased while the 
APP770 mRNA level remained constant in the HC Tg (apoB+A, bg+/") mouse group 
relative to the Wt animals (Fig. 6). 
The overexpression of the human apoB-100 and biglycan significantly (121%, /?=0.001) 
increased the levels of the membrane-bound APP isoforms in the Tg (apoB+/~, bg+/") mice 
(Fig. 8). The combined effect of the HC diet and the overexpression of the human apoB-
100 and biglycan also significantly (119%, /?=0.003) increased the levels of the 
membrane-bound APP isoforms relative to the Wt animals (Fig. 8). In the HC Tg (apoB+/", 
bg+/") group, the HC diet did not have a significant effect as compared with that in the 
soluble fraction of the cortices in the Wt controls (Fig. 8). 
Table 3. Effects of HC diet on the PKC and the BACE levels in cerebral cortex in the Wt, apoB Tg (apoBu ), 
[Tg (bg+/+)J, and Tg (apoB+/~, bg+/~) mouse groups 
Wt Tg (apoB+/+) Tg (bg+/+) Tg (apoB+/", HC diet-fed HC diet-fed HC diet-fed 
bg+/ ) Wt Tg (apoB+/+) Tg(apoB+/", bg+/") 
(n=5) (n=5) (n=5) (n =5) (n=5) (n=5) (n=5) 
PKC levels (OD) 
Soluble fraction 159.8±5.3 151.5±4.0 158.3±5.6 162.7±4.8 162.9±12.1 170.0±14.7 143.5±8.9 
Membrane-bound 170.1±7.1 171.9±6.5 162.2±4.9 149.7±9.7 177.7±3.0 150.8±9.7 168.9±6.5 
fraction 
BACE levels (OD) 154.1±4.3 133.3±2.7 149.5±11.4 159.6±8.6 141.2±5.5 147.9±9.0 139.3±12.3 
OD: Optical density. Values are expressed as means +SEM. 
4.10. PKC and BACE levels after dietary and genetic manipulations 
In order to investigate the possible regulation of the APP metabolism, the PKC and 
BACE protein levels were also monitored in the cortical samples. The HC diet did not 
change either the PKC (in the soluble or the membrane-bound fractions) or the BACE 
levels as compared with the Wt group (Table 3). In the case of overexpression of the 
human apoB-100 and biglycan genes, either individually or combined, no significant 
changes were found in either the soluble or the membrane-bound PKC levels. Similarly to 
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the PKC results, the BACE levels remained constant in each of the examined 
groups (Table 3). No differences were found either in the soluble or in the membrane-
bound PKC and the BACE levels when the HC diet-fed Tg (apoB+/+) and the HC Tg 
(apoB+/", bg+/") animals were examined (Table 3). 
4.11. ApoE polymorphism in a Hungarian cohort of Alzheimer's disease patients 
ApoE genotype and allele frequencies are presented in Table 4. The apoE allele 
frequencies were in Hardy-Weinberg equilibrium both in 
the CNT (x =9.04, df=5, 
p=0.107) and AD groups (x2=4.837, df=5,/?=0.436). The s4/4 genotype and s4 allele were 
over-represented in the AD group as compared with the CNT group (8% vs. 3.9% and 
23.2% vs. 11.3%, respectively). 
Table 4. ApoE genotypes and allele frequencies in CNT subjects and AD patients 
Figures in parentheses indicate frequencies (percentages {95% CI by Wilson's formula}) 
CNT AD 
apoE genotypes* (n = 102) (n = 125) 
(n % {CI}) (n % {CI}) 
2/2 - 1 (0.8% {0.004-5.0}) 
2/3 14(13.7% {7.9-22.3}) 10(8% {4.1-14.6}) 
2/4 - 1 (0.8% {0.004-5.0}) 
3/3 69 (67.6% {57.5-76.4}) 66 (52.8 {43.7-61.7}) 
3/4 15 (14.7% {8.73-23.4}) 37(29.6% {21.9-38.5}) 
4/4 4(3.9% {1.26-10.3}) 10(8% {4.1-14.6}) 
Allele** 
e2 14(6.9% {3.9-11.5}) 13 (5.2% {2.9-8.9}) 
e3 167 (81.9% {75.7-86.6}) 179 (71.6% {65.5-77.0}) 
84 23 (11.3% {7.4-16.6}) 58 (23.2% {18.2-29.0}) 
*CNTvs. AD Pearson f=12.409, df=5, p=0.03, exactp=0.015 
**CNTvs. AD Pearson f =11.029, df=2, p=0.004. 
4.12. CYP46 T/C polymorphism in a Hungarian cohort of Alzheimer's disease patients 
There was evidence of deviation from Hardy-Weinberg equilibrium in the case of 
CYP46 T/C polymorphism, when the AD population alone was examined (x2=7.671, df=2, 
p=0.022). However, no significant difference was found in the case of the CNT group 
(X2=4.92, df=2, /?=0.085). CYP46 T/C genotype and allele frequencies are presented in 
Table 5. No significant differences were observed between the distributions of CYP46 T/C 
genotypes and alleles, when the CNT and AD groups were compared (Table 5). 
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Table 5. CYP 46 genotypes and allele frequencies in CNT subjects and AD 
Figures in parentheses indicate frequencies (percentages, (95% CI by Wilson's formula}) 
CYP46 T/C 
genotypes* 
CNT 
(n = 102) 
in % (CD) 
AD 
(n = 125) 
in % (CD) 
T/T 50 (49% {39.5-58.6}) 54(43.2% {34.8-51.9}) 
T/C 49 (48% {38.5-57.6}) 66 (52.8% {44.1-61.3}) 
C/C 3 (3% {1.0-8.2}) 5 (4% {1.7-9.0}) 
Allele** 
T 149 (73% {65.5-78.6}) 174 (70% {63.6-74.9}) 
C 55 (27% {21.3-33.4}) 76 (30% {25.0-36.3}) 
*CNTvs. AD Pearson ¿=0.845, df=2, p = 0.655, exactp=0.712 
**CNTvs. AD Pearson ¿=0.647, df=l, p = 0.421, exact p=0.466, 
OR=0.845, 95% CI (0.561, 1.274) 
4.13. The interaction between the apoE e4 and CYP46 C alleles 
Table 6 lists thes frequencies and ORs for the interaction between the CYP46 C 
and apoE s4 alleles in the CNT and AD groups, divided into subgroups according to the 
apoE status (one or two s4+ or s4- carriers). The OR for the presence of one or two 
CYP46 C without the 
s4 allele was 1.628 (95% CI: 0.864-3.066) as compared with subjects with neither s4 nor 
CYP46 C. Since the OR 3.714 (95% CI: 1.549-8.908) for the presence of s4 without 
CYP46 C was similar to the OR 3.492 (95% CI: 1.401-8.707) for those with both e 4 and 
CYP C, we can exclude the synergistic effect of the two SNPs on the risk of AD in the 
examined population. 
Table 6. ORs for interaction between CYP46 C and apoE s4 alleles in AD and CNT subjects 
apoE £4 
allele 
CYP46 
C 
allele 
CNT 
n (%) 
AD 
n (%) 
OR (95% CI) 
P 
- - 40 (39.2) 28 (22.4) reference 
- + 43 (42.2) 49 (39.2) 1.628 (0.864-3.066) 0.131 
+ - 10(9.8) 26 (20.8) 3.714(1.549-8.908) 0.003 
+ + 9 (8.8) 22(17.6) 3.492(1.401-8.707) 0.007 
Model¿=13.176, df=3, p=0.004. 
36 
There were no significant differences in mean age by groups of CYP46 T/C alleles 
(F(2,220)=0.657, p=0.519), nor by groups of disease (F(l,220)=2.015, ¿>=0.157). The 
interaction was not significant between the age and the CYP46 T/C alleles 
(F(2,220)=0.818,/?=0.442). Gender was not significantly associated with CYP46T/C SNP 
either in the CNT group (x2=1.121, df=2, p=0.571, exact ¿>=0.564), or in the AD group 
(X2=0.231, df=2, ¿>=0.891, exact¿>=0.897). 
37 
5. Discussion 
5.1. Effects of HC diet on the serum TC and LDL cholesterol and MDA levels in Wt and 
apoB-100 Tg mice 
The Wt mouse lines are resistant to the effect of the HC diet. These animals are 
therefore protected against diet-induced hypercholesterolemia and do not develop AS 
(Breslow, 1996). However, the mouse Wt (C57BL/6) line used in our study is the most 
susceptible to the development of AS lesions upon administration of a HC diet (Jawien et 
al., 2004). In our experimental design, Tg mouse lines overexpressing the human apoB-
100 were generated by using this HC diet-susceptible Wt (C57BL/6) mouse line. 
In accordance with the expected results, we found a relative resistance in the serum 
TC and LDL cholesterol levels of the Wt animals to the HC diet, whereas in response to 
the HC diet, the serum TC and LDL cholesterol levels were increased in the apoB-100 Tg 
mice, due to the fact that cholesterol was carried by their human apoB-100-containing 
lipoproteins. These and previous observations indicate that the reason for the serum TC 
and LDL cholesterol differences between the Wt and the Tg mice may be their different 
lipoprotein profiles and cholesterol metabolisms (Kim and Young, 1998; Purcell-Huynh et 
In addition, a previous study revealed that the MDA levels were increased in both 
the plasma and the aorta after feeding with the HC diet (1% w/w) for 2 months (Balkan et 
al., 2002). In our study, the HC diet resulted in concomitant increases in serum markers of 
oxidative stress in the Wt and the apoB-100 Tg animals. Furthermore, several studies have 
confirmed that the HC diet is accompanied by an increased oxLDL level (Berliner et al., 
1995; Schwenke and Carew, 1989; Young and Parthasarathy, 1994). Our finding is 
consistent with an earlier observations of significant increases in the levels of MDA in 
mice fed with cholesterol (1.5%) for a period of 6 weeks and after a cholesterol-treatment 
period of 8 weeks in Watanabe heritable hyperlipidemic rabbits (Lauridsen and 
Mortensen, 1999). Moreover, others found that the brain MDA was increased in New 
Zealand white rabbits that received 1% cholesterol plus regular chow (Aydemir et al., 
2000). Our findings indicate that cholesterol feeding influenced the prooxidant-antioxidant 
status in the organism. Unfortunately, no data are available regarding the effect of a HC 
diet on the MDA level in the brain in the experimental model of AD. 
al., 1995) 
> \ 
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5.2. Isolated and combined effects of HC diet and human apoB-100 gene overexpression 
on cortical APP metabolism in Tg mice 
We found that, despite the reported relative resistance in the serum cholesterol 
levels of the Wt (C57BL/6) animals, the HC diet increased the levels of both APP695 and 
APP770 mRNAs in their cortex, which remained on the same level even in the apoB-100 
Tg group. In the only published study on primary glial and neuronal cell lines, cholesterol 
treatment significantly decreased the total APP mRNA levels (Galbete et al., 2000). 
However, no synergistic effect was found in the case of the APP mRNA levels when the 
two atherogenic factors, the HC diet and the overexpression of the human apoB-100 gene, 
were applied together in our study. No other data are available regarding the effect of the 
overexpression of the human apoB-100 gene on cerebral APP mRNA levels. It is not 
known why the HC treatment did not further increase the APP mRNA levels in the apoB-
100 Tg animals. Further investigations are necessary to study the different regulatory 
mechanisms of gene transcription. 
Additionally, we investigated the extent of translation of the total APP products by 
immunoblotting in the soluble and membrane-bound fractions of the cerebral cortex. The 
membrane-bound APP levels were significantly elevated by the HC diet in both the Wt 
and the apoB-100 Tg animals. It is noteworthy, however, that in response to the HC diet 
the membrane-bound APP levels were even more elevated in the apoB-100 Tg and in the 
double Tg mice than in the Wt animals. 
The results presented here indicate that the levels of the APP isoforms in the 
soluble fraction decrease in response to a HC diet. This perturbation may be a result of the 
stiffening of the cell membrane by the cholesterol load, possibly inhibiting the lateral 
movement of the APP and its cleaving enzymes and decreasing the required contact 
between the secretases and their APP substrate (Bodovitz and Klein, 1996). In addition, 
APPs-a may serve as a neuroprotective agent against hypoglycemic damage and oxidative 
toxicity (Araki et al., 1991; Mattson et al., 1993), and its reduction could exacerbate cell 
death in AD (Bodovitz and Klein, 1996). In conclusion, the overexpression of the human 
apoB-100 gene did not change the APP metabolism, whereas the HC diet individually and 
in combination with the overexpression of the human apoB-100 gene could alter the mode 
of APP processing into the route of Ap production. 
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5.3. Human biglycan gene overexpression interferes with the cortical APP metabolism 
in Tg mice 
It is tempting to speculate that biglycan may promote the extracellular lipid 
accumulation and formation of the oxidatively modified LDL in the endothel. As a 
consequence, it is proposed that this interaction may contribute to the processes of AS and 
subsequent VD and AD. Our results indicated that biglycan increased the APP770 mRNA 
level relatively more than the APP695 mRNA level in the cortex. This is an important 
finding, since a similar tendency was observed in the AD brain. Earlier reports suggested 
that isoforms containing KPI are preferentially expressed in the AD brain, whereas 
APP695 is reduced (Rockenstein et al., 1995). Other authors have also demonstrated that 
the APP-770/APP-695 mRNA ratio is generally increased during AD (Johnson et ah, 
1990). However, according to our findings overexpression of the human biglycan did not 
have a significant effect on the levels of the APP isoforms in either the soluble or the 
membrane-bound fractions in the cortices of the biglycan Tg mice. It is not known why the 
overexpression of the human biglycan did not alter the levels of the APP isoforms. 
Biglycan may also be important in modifying APP mRNA alternative splicing in the brain. 
Further experiments are required to study which regulatory mechanisms of gene 
transcription are followed. 
5.4. Atherogenic risk factors modulate the cortical APP metabolism in the double Tg 
mouse model of atherosclerosis 
The overexpression of the human apoB-100 and biglycan genes and the HC diet 
increase the membrane-bound APP levels in the double Tg mice. To best of our 
knowledge, this is the first study in which the interaction between the HC diet and the 
apoB-100 and biglycan in the transgenic mice was examined. The human apoB-100 and 
biglycan extra genes or the HC diet together might therefore have a direct or indirect 
synergistic influence on the subcellular localization of the APP isoforms. One possible 
explanation for the increased amount of APP isoforms in the membrane-bound fractions is 
that the BACE activity might be changed in both the HC diet-fed Wt, the apoB-100 Tg 
and the double Tg mice. Taken together, the HC diet individually and in combination with 
the overexpression of the human apoB-100 and biglycan genes may promote the abnormal 
processing of APP and probably leads to the formation of Ap. 
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5.5. Atherogenic risk factors do not interact with the brain PKC and BACE levels 
It was previously found that BACE is up-regulated by increased intracellular 
cholesterol levels, and down-regulated by the inhibition of cholesterol biosynthesis in vitro 
(Sidera et al., 2005). Surprisingly, the BACE levels were not altered in the cortices of the 
animals treated with the HC diet and the peripheral overexpression of the human apoB-
100 or biglycan genes. One possible explanation for this discrepancy is that the previous 
results were obtained from different model systems. Another possible explanation is that 
not the BACE levels per se, but rather the activity of this membrane-integrated protein 
was modified by the treatment applied in the present study. 
PKC is known to be a regulator of the a-secretory proteolytic processing of the 
APP molecule (Skovronsky et al., 2000). In our experiment, the levels of the APP 
isoforms in the soluble fraction were found to be decreased by the HC diet in the Wt 
animals. For this reason decreased cortical PKC proteins would also be expected. In 
contrast, there were no changes in either the soluble or the membrane-bound fractions in 
the studied groups. These findings indicate that neither the HC diet nor the increased 
expression of the human apoB-100 and biglycan genes is likely to interfere with the APP 
metabolism through the PKC signal transduction pathway. 
5.6. Atherogenic risk factors do not influence the serum, liver and brain AC/tE and 
BChE activities of Tg animals 
AChE may also be involved in the lipid metabolism and the BChE activity is 
positively correlated with the serum triglyceride, cholesterol and apoB levels (Alcantara et 
al., 2002). It has also been reported that there is an association between the inheritance of 
the apoE e4 allele and the extent of cholinergic dysfunction in AD (Cedazo-Minguez and 
Cowburn, 2001). These studies suggest that mice deficient in apoE may exhibit impaired 
central cholinergic function (Anderson and Higgins, 1997). We, therefore investigated the 
effects of the HC diet on the AChE and BChE levels in the brain, liver and serum. 
However, our results did not confirm the earlier observations. No other in vivo data are 
available regarding the effects of the overexpression of the human apoB-100 or the 
biglycan genes on the AChE and BChE levels. It is unlikely, therefore, the examined 
dietary and genetic atherogenic risk factors interfere with the activities of the enzymes 
responsible for the degradation of ACh. 
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5.7. The polymorphism of CYP46 Al is not associated with Alzheimer's disease in the 
Hungarian population 
Although the CYP46 gene is a good candidate for potential involvement in the 
proposed pathomechanism of AD, we provide here evidence that the intron 2 and T/C SNP 
do not confer susceptibility to this type of dementia in the Hungarian ethnic group. Other 
studies have reported similar findings, a negative association between CYP46 T/C 
polymorphism and AD (Chalmers et al., 2004; Desai et al., 2002; Kabbara et al., 2004; 
Kölsch et al., 2002) in different African-American and Caucasian populations from North 
America and Europe. The opposite finding, a positive association of the CYP46 
polymorphism, was found to be associated with AD in independent populations and 
different ethnic groups from Asia and Europe (Borroni et al., 2004; Combarros et al., 
2004; Johansson et al., 2004; Kölsch et al., 2002; Wang et al., 2004). The discrepancy 
between the different studies may be a result of ethnic or methodological differences or 
both. 
5.8. No interaction exists between the apoE e4 and CYP46 C alleles in the Hungarian 
Alzheimer's disease population 
There is a synergistic increase in the risk of AD in persons who carry CYP46C and 
apoE c4 alleles. Those carrying CYP46C and apoEs4 variants are almost 10 times more 
likely to develop AD than those with neither variation (Papassotiropoulos et al., 2003). 
Our case-control study was therefore performed on subjects from Hungary, to test the 
interaction of these alleles in AD. 
It is pertinent to mention here that the normal Hungarian population is considered 
to differ from other European ethnic groups in connection with another risk gene for AD, 
the apoE s4 allele distribution (Hallman et al., 1991). Perhaps this is the reason why the 
frequency of the allele apoE s4 was lower (23%) even in the Hungarian AD population in 
the present study than is other AD groups reported from Europe. However, the proportion 
of the e4 allele carriers (11%) was still significantly higher in the Hungarian AD 
population than in the CNT group. The percentage distribution of the apoE genotypes and 
frequencies in our present investigation confirmed the findings of our previous studies on 
different control and AD groups from the same country (Kálmán et al., 1998; McConathy 
et al., 1997). Our findings are not in accord with a previous report where the CYP46 C and 
e4 alleles together are risk factors for AD (Borroni B. 2004). In summary, our data 
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indicate that it is unlikely that the intron 2 CYP46 T/C polymorphism, either alone or 
together with the s4 allele, is a risk factor for AD in the Hungarian population. 
43 
6. Limitations 
6.1. One possible limitation of the present study is that we did not determine the brain 
cholesterol levels in the Wt and the Tg animals. Recent evidence has been reported, 
however, that marked changes can be induced by a 2% HC diet in the fatty acid 
composition of the phospholipids of the brain of C57/B6 x CBA mice (Puskás et 
al„ 2004). 
6.2. Another weakness of our work was that the HC diet was not applied to the biglycan 
Tg mice. Further investigations are therefore necessary with the overexpression of 
biglycan Tg mice after feeding with a HC diet. 
6.3. An additional limitation of our SNP studies may be the relatively small number of 
the examined Hungarian population. 
7. Summary of the major findings and conclusions 
7.1.1. The Wt (C57BL/6) mice exhibited a relative resistance to the effect of the HC diet. 
The 
significantly elevated serum MDA levels indicate more oxidized lipids which 
might play role in the formation of AS plaque. 
Due to the overexpression of the human apoB-100, the HC diet increased the TC 
and the LDL cholesterol levels in the Tg (apoB+/+) mice. The increased MDA level 
in the Tg (apoB+/+) mice denotes oxidative stress and lipid peroxidation caused by 
the HC diet. 
7.1.2. The HC diet increased the brain APP695 and APP770 mRNA levels in the Wt 
mice, 
whereas the HC diet also increased the membrane-bound fraction of APP in the Wt 
and 
Tg (apoB+/+) animals. These results indicate that the changes in peripheral 
cholesterol metabolism individually and in combination with the overexpression of 
the human apoB-100 gene may result in an elevated cholesterol content of the cell 
membrane and therefore alter the gene expression of APP and/or facilitate the P-
and y-cleavage of APP. However, the overexpression of the human apoB-100 gene 
individually did not interfere with the APP metabolism. 
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7.1.3. The human biglycan gene overexpression influences the gene expression of APP. 
Overexpression of this transgene increased the APP770 mRNA level relatively 
more than the APP695 mRNA level in the cortex of the Tg (bg+/+) mice. 
7.1.4. Individually, overexpression of the human apoB-100 and biglycan genes increased 
the membrane-bound fraction of APP in the double Tg mouse model of AC. The 
combined effect of the human apoB-100 and biglycan or the HC diet also increased 
the APP695 mRNA and the membrane-bound fraction of APP. These results 
indicate that the HC diet and these atherogenic factors possibly enhance the gene 
expression of APP and/or facilitate its P- and y-cleavage. 
7.1.5. The BACE levels were not altered in the cortices of the animals treated with the 
HC diet or by the overexpression of the human apoB-100 or biglycan genes. The 
HC diet and the increased expression of human apoB-100 and biglycan genes are 
not likely to interfere with the APP metabolism through the BACE levels or the 
PKC signal transduction pathway. 
7.2. Overexpression of the human apoB-100 and biglycan genes or the HC diet did not 
influence the AChE and BChE activities in the serum, liver and brain of the Tg 
animals. It is unlikely, therefore, that under these conditions either the 
overexpression of the human apoB-100 and biglycan genes or the HC diet 
modulates the activities of these enzymes. 
7.3.1. Inheritance of the CYP46A1 C allele was not associated with AD in the examined 
Hungarian population. Accordingly the polymorphism of CYP46 A1 is unlikely to 
confer a higher risk of sporadic AD in this ethnic group. 
7.3.2. We did not observe an interaction between the apoE s4 and CYP46 C alleles in the 
examined Hungarian population. However, the proportion of the e4 allele carriers 
was still significantly higher among the AD probands. Hence, it is unlikely that 
intron 2 CYP46 T/C polymorphism, either alone or together with the e4 allele, is a 
risk factor for AD in the Hungarian population. 
In our study, a new transgenic mouse (apoB-100 and biglycan) model of AS was 
developed. This mice should furnish a possibility for study of the the role of the HC diet, 
AS and the APP metabolism in the brain. Furthermore, these transgenic animal models 
could facilitate future investigations of the interaction between the APP metabolism and 
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the cholesterol metabolism in the CNS, and might provide further information relating to 
pathomechanism of AD. Focusing on the relationship between cholesterol and APP 
metabolism would be important not only for etiological, but also for therapeutic purposes. 
Our study has confirmed the concept that anti-atherogenic therapy, including dietary 
regimens, may be effective in the prevention and treatment of such type of dementia. 
Further, in the examined Hungarian group we demostrated that inheritance of the 
apoE E4 allele is an independent risk factor for AD, but we could not confirm the same 
effect in the case of another gene (CYP46) associated with lipid metabolism. 
The improved knowledge resulting from such studies may promote an 
understanding of the function of the HC diet in the progress of AD, and may facilitate the 
development of drugs associated with the lipid metabolism as potential candidates for the 
treatment of AD. 
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